All In Biotech

Drug Trial Radar · NCT04615273

A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency

foresiGHt: A Multicenter, Randomized, Parallel-arm, Placebo-controlled (Double- Blind) and Active-controlled (Open-label) Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency

Last checked: Nov 20, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 264 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

264

Actual

Start

Dec 3, 2020

Primary completion

Nov 2, 2023

Study completion Dec 1, 2023

Sponsor

Sponsor type
Industry
First posted
Nov 4, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 23 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A 38-week dosing trial of lonapegsomatropin, a long-acting growth hormone product, administered once-a-week versus placebo-control. A daily somatropin product arm is also included to assist clinical judgement on the trial results. A total of 264 adults (males and females) with growth hormone deficiency were included. Randomization occurred in a 1:1:1 ratio (lonapegsomatropin: placebo: daily somatropin product). This is a global trial conducted in, but not limited to, the United States, Europe, and Asia.

Conditions

  • Growth Hormone Deficiency
  • Endocrine System Diseases
  • Hormone Deficiency

Interventions

  • LonapegsomatropinDrug

    Due to the different human growth hormone (hGH) dose requirements, depending on participant's age and concomitant use of oral estrogen, this trial has 3 dosing groups per arm, followed by gradual increasing dose titration to a target maintenance dose.

  • PlaceboOther

    The placebo for lonapegsomatropin drug product contained the same excipients as lonapegsomatropin drug product but does not contain lonapegsomatropin itself. The placebo solution was administered by subcutaneous (SC) injection via syringe and needle. Due to the different hGH dose requirements, depending on participant's age and concomitant use of oral estrogen, this trial has 3 dosing groups and the placebo received the same dose volume as if they were randomized to once-weekly lonapegsomatropin.

  • SomatropinDrug

    Somatropin solution is provided in a pre-filled pen intended for daily subcutaneous injection. Due to the different hGH dose requirements, depending on participant's age and concomitant use of oral estrogen, this trial has 3 dosing groups per arm, followed by gradual increasing dose titration to a target maintenance dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Trunk Percent Fat at Week 38Time frame: Baseline, Week 38

Locations

113 sites in 24 countries. Site status is shown where the registry gives one.

  • Ascendis Pharma Investigational Site

    Birmingham, Alabama

  • Ascendis Pharma Investigational Site

    Phoenix, Arizona

  • Ascendis Pharma Investigational Site

    Fresno, California

  • Ascendis Pharma Investigational Site

    Los Angeles, California

  • Ascendis Pharma Investigational Site

    Los Angeles, California

  • Ascendis Pharma Investigational Site

    Palo Alto, California

  • Ascendis Pharma Investigational Site

    Torrance, California

  • Ascendis Pharma Investigational Site

    Chicago, Illinois

  • Ascendis Pharma Investigational Site

    Indianapolis, Indiana

  • Ascendis Pharma Investigational Site

    Boston, Massachusetts

  • Ascendis Pharma Investigational Site

    Dearborn, Michigan

  • Ascendis Pharma Investigational Site

    Rochester, Minnesota

  • Ascendis Pharma Investigational Site

    St Louis, Missouri

  • Ascendis Pharma Investigational Site

    Las Vegas, Nevada

  • Ascendis Pharma Investigational Site

    Reno, Nevada

  • Ascendis Pharma Investigational Site

    New York, New York

  • Ascendis Pharma Investigational Site

    New York, New York

  • Ascendis Pharma Investigational Site

    Morehead City, North Carolina

  • Ascendis Pharma Investigational Site

    Portland, Oregon

  • Ascendis Pharma Investigational Site

    Pittsburgh, Pennsylvania

  • Ascendis Pharma Investigational Site

    Dallas, Texas

  • Ascendis Pharma Investigational Site

    San Antonio, Texas

  • Ascendis Pharma Investigational Site

    Seattle, Washington

  • Ascendis Pharma Investigational Site

    Yerevan, Armenia

  • Ascendis Pharma Investigational Site

    Saint Leonards, New South Wales, Australia

  • Ascendis Pharma Investigational Site

    Sydney, New South Wales, Australia

  • Ascendis Pharma Investigational Site

    Box Hill, Victoria, Australia

  • Ascendis Pharma Investigational Site

    Fitzroy, Victoria, Australia

  • Ascendis Pharma Investigational Site

    Parkville, Victoria, Australia

  • Ascendis Pharma Investigational Site

    Perth, Western Australia, Australia

  • Ascendis Pharma Investigational Site

    Vancouver, British Columbia, Canada

  • Ascendis Pharma Investigational Site

    Halifax, Nova Scotia, Canada

  • Ascendis Pharma Investigational Site

    Copenhagen, Denmark

  • Ascendis Pharma Investigational Site

    Lyon, France

  • Ascendis Pharma Investigational Site

    Marseille, France

  • Ascendis Pharma Investigational Site

    Nantes, France

  • Ascendis Pharma Investigational Site

    Paris, France

  • Ascendis Pharma Investigational Site

    Tbilisi, Georgia

  • Ascendis Pharma Investigational Site

    Tbilisi, Georgia

  • Ascendis Pharma Investigational Site

    München, Bavaria, Germany

Showing 40 of 113 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.